Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Xiuning Le MD, PhD

Xiuning Le MD, PhD

Assistant Professor, University of Texas M.D. Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, Houston, TX

As an Assistant Professor in the Thoracic/Head and Neck department, Dr. Le has a clinical and research expertise in treating oncogene-driven non-small cell lung cancer.

Educational background

Dr. Le earned her medical degree from the Peking Union Medical College (PUMC) and Ph.D. degree in Biological and Biomedical Sciences at Harvard Medical School (HMS) in Boston. She completed her internship and residency at the University of Massachusetts Medical Center in Worcester, MA. She then completed a hematology/oncology fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School. During the research fellowship at Dana-Farber Cancer Institute (DFCI), she focused on genomics approaches to understand cancer resistance. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology.

Professional highlights and publications/awards

Dr. Le’s research focuses on improving targeted therapeutics for lung cancer, bringing new actionable targets to lung and head/neck cancer, developing novel biomarkers in precision oncology. She and her colleagues have published high-impact journal articles, including New England Journal of Medicine, Nature, Journal of Clinical Oncology, Cancer Discovery. The clinical trials led by Dr. Le has resulted in FDA approval of novel targeted therapy in lung cancer.

Dr. Le has received numerous awards and grants, including ASCO Young Investigator Award and Career Development Award, Paul Calabresi Award, SU2C-TVF Convergence Scholar, Claudia Adams Barr for Innovative Cancer Research Award, Stiefel Foundation, Rexanna Foundation, Khalifa Foundation and other awards.

Disclosures

Conflict of interest

Dr. Le receives consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics, Janssen, and Abbvie, and Research Funding from Eli Lilly, EMD Serono, Regeneron, and Boehringer Ingelheim.

Recent Contributions to PracticeUpdate:

  1. Poziotinib in Previously Treated NSCLC Harboring HER2 Exon 20 Insertion Mutations
  2. T-DM1 for Patients With NSCLC Positive for HER2 Exon-20 Insertion Mutations

Recently Updated